Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Orticumab by Abcentra for Inflammation: Likelihood of Approval
Orticumab is under clinical development by Abcentra and currently in Phase II for Inflammation. According to GlobalData, Phase II drugs...
Data Insights
Orticumab by Abcentra for Acute Coronary Syndrome: Likelihood of Approval
Orticumab is under clinical development by Abcentra and currently in Phase II for Acute Coronary Syndrome. According to GlobalData, Phase...